Main public logs

Combined display of all available logs of Azupedia. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

• 17:10, 14 March 2024 Fire talk contribs created page Translations:Glimepiride/9/ja (Created page with "== 医療用途 == {{Anchor|Medical uses}} left|thumb|グリメピリドのジェネリック経口錠2錠、各2mg グリメピリドは2型糖尿病の治療に適応があり、その作用機序は膵臓からのインスリン分泌を増加させることである。作用機序は膵臓からのインスリン分泌を増加させることであるが、適切な治療には前提として十分な...")
• 17:09, 14 March 2024 Fire talk contribs created page Translations:Glimepiride/8/ja (Created page with "<!-- Society and culture --> グリメピリドは1979年に特許を取得し、1995年に医療用として承認された。これはジェネリック医薬品として入手可能である。2021年には、米国で74番目に多く処方された薬であり、8{{nbsp}}万以上の処方があった。")
• 17:08, 14 March 2024 Fire talk contribs created page Translations:Glimepiride/7/ja (Created page with "<!-- Side effects and mechanisms --> 一般的な副作用には、頭痛、吐き気、めまいなどがある。重篤な副作用には低血糖が含まれることがある。妊娠中および授乳中の使用は推奨されない。第二世代スルホニルウレアに分類される。")
• 23:24, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/15/ja (Created page with "== 薬物動態 == {{Anchor|Pharmacokinetics}} 消化管吸収は完全で、食事による影響はない。有意な吸収は1時間以内に起こり、全身に分布し、99.5％が血漿タンパク質に結合する。代謝は酸化的生体内変換によるもので、肝臓で完全に行われる。まず、医薬品はCYP2C9によってM₁代謝物に代謝される。M₁はグリメピリドの薬理活性の{...")
• 23:22, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/16/ja (Created page with "{{Oral hypoglycemics/ja}} {{Prostanoidergics/ja}} {{Ion channel modulators/ja}} {{Portal bar | Medicine}}")
• 23:21, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/17/ja (Created page with "Category:Potassium channel blockers Category:1-(Benzenesulfonyl)-3-cyclohexylureas Category:Gamma-lactams Category:Sanofi Category:Wikipedia medicine articles ready to translate")
• 22:57, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/6/ja (Created page with "<!-- Chemical data --> | IUPAC_name = 3-Ethyl-4-methyl-''N''-[2-(4-<nowiki/>{[(''trans''-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1''H''-pyrrole-1-carboxamide | C = 24 | H = 34 | N = 4 | O = 5 | S = 1 | smiles = O=C3C(/CC)=C(/C)CN3C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2 | StdInChI_Ref = {{stdinchicite|correct|chemspide...")
• 22:55, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/5/ja (Created page with "<!--Identifiers--> | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 93479-97-1 | PubChem = 3476 | IUPHAR_ligand = 6820 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB00222 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 16740595 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 6KY687524K | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG...")
• 22:55, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/4/ja (Created page with "<!--Pharmacokinetic data--> | bioavailability = 100% | protein_bound = >99.5% | metabolism = 完全な肝臓（第1段階からCYP2C9まで） | onset = 2–3時間 | elimination_half-life = 5–8時間 | duration_of_action = 24時間 | excretion = 尿中 (~60%), 糞中 (~40%)")
• 22:55, 13 March 2024 Fire talk contribs created page Glimepiride/ja (Created page with "{{drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 412761821 | image = Glimepiride.svg | width = 300") Tags: Mobile edit Mobile web edit
• 22:54, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/3/ja (Created page with "| legal_AU = S4 | legal_US = Rx-only | legal_status = Rx only")
• 22:54, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/2/ja (Created page with "<!-- Clinical data --> | tradename = アマリール, その他 | Drugs.com = {{drugs.com|monograph|glimepiride}} | MedlinePlus = a696016 | DailyMedID = Glimepiride | pregnancy_AU = C | routes_of_administration = By mouth | ATC_prefix = A10 | ATC_suffix = BB12 | ATC_supplemental =")
• 22:54, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/1/ja (Created page with "{{drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 412761821 | image = Glimepiride.svg | width = 300")
• 22:53, 13 March 2024 Fire talk contribs created page Translations:Glimepiride/Page display title/ja (Created page with "グリメピリド")
• 22:53, 13 March 2024 Fire talk contribs marked Glimepiride for translation
• 22:53, 13 March 2024 Fire talk contribs limited languages for translatable page Glimepiride to Japanese
• 22:52, 13 March 2024 Fire talk contribs created page Category:Gamma-lactams (Created page with "{{Commonscat}} Γ Category:Five-membered rings")
• 22:52, 13 March 2024 Fire talk contribs created page Category:1-(Benzenesulfonyl)-3-cyclohexylureas (Created page with " {{DEFAULTSORT:Benzenesulfonyl-3-cyclohexylureas, 1-}} Category:Benzenesulfonylureas Category:Cyclohexyl compounds")
• 22:52, 13 March 2024 Fire talk contribs created page Category:Potassium channel blockers (Created page with "{{Commons category|Potassium channel blockers}} {{Cat main|Potassium channel blockers}} Category:Ion channel blockers Category:Antiarrhythmic agents Category:Potassium channels")
• 22:51, 13 March 2024 Fire talk contribs created page Category:Drugboxes which contain changes to verified fields (Created page with "{{polluted category}} {{hidden category}}{{Chemical data validation}} This category contains pages which have been tagged by User:CheMoBot as having 'verified' fields which have been changed since the page has been verified (see Wikipedia:WikiProject Chemicals/Chembox validation). V Chemical data validation {{CatAutoTOC}}")
• 22:51, 13 March 2024 Fire talk contribs created page Category:Articles with changed DrugBank identifier (Created page with "{{hidden category}}{{empty category}} {{Chemical data validation|state=collapsed}} Filled by {{tl|Chembox}}. This category contains pages which have been tagged by User:CheMoBot as having a verified '''DrugBank''' (for {{tl|chembox}}) and {{tl|drugbox}}) field which has been changed since the page has been verified (see Wikipedia:WikiProject Chemicals/Chembox validation). DrugBank Category:Chemboxes which contain...")
• 22:49, 13 March 2024 Fire talk contribs created page immunotherapy (Q21477) (wbeditentity-create:2|en: immunotherapy, therapy to elicit or amplify an immune response)
• 22:48, 13 March 2024 Fire talk contribs created page immunosuppression (Q21476) (wbeditentity-create:2|en: immunosuppression, decreased resistance to infection; reduction of the activation or efficacy of the immune system)
• 22:47, 13 March 2024 Fire talk contribs created page immunologic factor (Q21475) (wbeditentity-create:2|en: immunologic factor, biologically active substance whose activities affects or plays a role in the functioning of the immune system)
• 22:47, 13 March 2024 Fire talk contribs created page immunosuppressive drug (Q21474) (wbeditentity-create:2|en: immunosuppressive drug, agent that suppresses immune function by one of several mechanisms of action (e.g. inhibiting DNA synthesis, inhibiting activation of T-cells, or inhibiting the activation of helper cells))
• 22:45, 13 March 2024 Fire talk contribs created page antiarrhythmic agent (Q21473) (wbeditentity-create:2|en: antiarrhythmic agent, pharmaceutical used to suppress abnormal rhythms of the heart)
• 22:42, 13 March 2024 Fire talk contribs created page glimepiride (Q21472) (wbeditentity-create:2|en: glimepiride, group of stereoisomers)
• 22:41, 13 March 2024 Fire talk contribs created page Template:Prostanoid signaling modulators/ja (Created page with "{{Navbox | name = Prostanoid signaling modulators/ja | title = Prostanoid/ja伝達モジュレーター | state = {{{state<includeonly>|collapsed</includeonly>}}} | bodyclass = hlist | groupstyle = text-align:center; | group1 = 受容体<br /><small>(リガンド)</small> | list1 = {{Navbox|child | groupstyle = text-align:center; | groupwidth = 5em; | grou...")
• 22:12, 13 March 2024 Fire talk contribs created page Template:Prostanoid signaling modulators (Created page with "{{Navbox | name = Prostanoid signaling modulators | title = Prostanoid signaling modulators | state = {{{state<includeonly>|collapsed</includeonly>}}} | bodyclass = hlist | groupstyle = text-align:center; | group1 = Receptor<br /><small>(ligands)</small> | list1 = {{Navbox|child | groupstyle = text-align:center; | groupwidth = 5em; | group1 = {{abbrlink|DP (D<sub>2</s...")
• 22:12, 13 March 2024 Fire talk contribs created page Template:Prostanoidergics/ja (Redirected page to Template:Prostanoid signaling modulators/ja) Tag: New redirect
• 22:11, 13 March 2024 Fire talk contribs created page Template:Prostanoidergics (Redirected page to Template:Prostanoid signaling modulators) Tag: New redirect
• 22:10, 13 March 2024 Fire talk contribs created page Glimepiride (Created page with "{{Short description|Medication}} {{drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 412761821 | image = Glimepiride.svg | width = 300 <!-- Clinical data --> | tradename = Amaryl, others | Drugs.com = {{drugs.com|monograph|glimepiride}} | MedlinePlus = a696016 | DailyMedID = Glimepiride | pregnancy_AU = C | routes_of_administration = Oral administration|By mouth...")
• 08:59, 13 March 2024 Fire talk contribs created page Antidiabetic drug/ja (Redirected page to 糖尿病治療薬) Tag: New redirect
• 08:59, 13 March 2024 Fire talk contribs created page Antidiabetic drug (Redirected page to Diabetes medication) Tag: New redirect
• 08:55, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/30/ja (Created page with "除草剤としてのスルホニル尿素の研究開発（トランスレーショナルリサーチと商業的応用開発）は1970年代と1980年代に行われ、例えば農業の社会技術的側面に焦点を当てたスローン・テクノロジー・シリーズの1巻（Canine 1995）で紹介されている。デュポン実験場がこの開発を主導した。")
• 08:53, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/29/ja (Created page with "スルホニル尿素の医薬品（糖尿病前症および糖尿病の診断薬および治療薬）としての研究開発（トランスレーショナルリサーチおよび商業的応用開発）は、''トルブタミド § ヒストリー''で検討したように、1950年代から1960年代にかけて行われた。")
• 08:50, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/28/ja (Created page with "===歴史=== スルホニル尿素は1942年、スルホンアミド抗生物質を研究していた化学者マルセル・ジャンボンとその共同研究者によって化合物が動物に低血糖症を引き起こすことを発見した。")
• 08:47, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/27/ja (Created page with "さらに、スルホニル尿素はヌクレオチド交換因子Epac2と相互作用することが示されている。この因子を欠損したマウスでは、スルホニルウレア剤投与によるグルコース低下作用が低下した。")
• 08:46, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/26/ja (Created page with "K_ATPチャネルは、内向き直流カリウムイオンチャネルの8量体複合体である。K_ir6.xとスルホニルウレア受容体の複合体である。SURが4:4の化学量論で結合している。")
• 08:45, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/25/ja (Created page with "また、スルホニル尿素はβ細胞をグルコースに対して感作し、肝臓でのグルコース産生を制限し、脂肪分解（脂肪組織による脂肪酸の分解と放出）を減少させ、肝臓によるインスリンのクリアランスを減少させるという証拠もある。")
• 08:43, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/24/ja (Created page with "スルホニル尿素は、膵β細胞の細胞膜上のATP感受性K⁺(K_ATP)チャネルに結合して閉じ、カリウムが外に出るのを妨げることによって細胞を脱分極させる。この脱分極は、電位依存性Ca²⁺チャネルを開く。細胞内カルシウムの上昇は、インスリン顆粒と細...")
• 08:40, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/23/ja (Created page with "===分類=== スルホニル尿素は、その抗糖尿病作用の治療効率に基づいて3つのクラスに分類される： * 第一世代の薬剤： アセトヘキサミド、カルブタミド、クロルプロパミド、グリシクラミド（トルサイクラミド）、メタヘキサミド、トラザミド、tolbutamide/ja|トル...")
• 08:35, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/22/ja (Created page with "<gallery> image:Chlorpropamide.svg|Chlorpropamide/ja (第一世代) image:Tolazamide.svg|Tolazamide/ja (第一世代) image:Gliclazide.svg|Gliclazide/ja (第二世代) image:Glimepiride.svg|グリメピリド (第二世代) </gallery>")
• 08:32, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/21/ja (Created page with "== 構造 == {{Anchor|Structure}} スルホニル尿素は、フェニル環（'''R¹'''）上の''p''-置換基と、尿素''N''{{prime}}末端基（'''R²'''）を末端とする様々な基を有する中心的な'''S''-arylsulfonylurea構造を含む。化学的には、この官能性はアリールを反応させることで容易に導入できる。スルホンアミド（R¹-C₆H₄...")
• 08:25, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/20/ja (Created page with "スルホニル尿素薬の作用を増強または延長させ、低血糖のリスクを増大させる薬物には、アセチルサリチル酸およびその誘導体、アロプリノール、sulfonamide (medicine)スルホンアミド、フィブラートなどがある。抗糖尿病薬の効果に反して耐糖能を悪化させる薬物には、corticosteroid/ja|コル...")
• 07:55, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/19/ja (Created page with "=== 相互作用 ===")
• 07:55, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/18/ja (Created page with "第二世代のスルホニルウレア薬は第一世代のスルホニルウレア薬と比較して、重量による効力が増加している。 同様に、ACCORD（Action to Control Cardiovascular Risk in Diabetes）試験やVADT（Veterans Affairs Diabetes Trial）試験では、様々な薬剤で厳格な血糖コントロールを行った患者において、心臓発作や死亡の減少はみられなかった。")
• 07:44, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/17/ja (Created page with "2020年の|コクランでは メトホルミン単剤療法とスルホニル尿素薬を比較したシステマティックレビューでは、全死亡、重篤な有害事象、心血管死亡、非致死的心筋梗塞、非致死的脳卒中、または末期腎不全を減少させるという十分なエビデンス...")
• 07:33, 13 March 2024 Fire talk contribs created page Translations:Sulfonylurea/16/ja (Created page with "2014年のコクランのレビューでは、スルホニル尿素薬による治療はメトホルミンによる治療よりも非致死的心血管系イベントが少ないが（RR 0.7）、重症低血糖のリスクが高い（RR 5.6）という暫定的なエビデンスが示された。死亡率や心血管死亡のリスクを決定するのに十分なデータはなかった。同じグループによる以前のレビューでは、第一世代スルホニ...")
• 22:51, 12 March 2024 Fire talk contribs created page Category:Schering-Plough (Created page with "{{Commons category|Schering-Plough}} *'''Schering-Plough''' (1971−2009) — a {{C|Defunct pharmaceutical companies of the United States|defunct pharmaceutical companies of the United States}}, based in New Jersey until acquired by {{C|Merck & Co.}}. Category:Defunct pharmaceutical companies of the United States Category:Merck & Co. Category:Schering AG Category:American companies established in 1971 Category:Pharmaceutical companies establish...")